CPT code 86692 identifies a laboratory immunoassay for antibodies to hepatitis D (delta agent). This diagnostic test supports clinical evaluation of suspected hepatitis D infection in patients with hepatitis B co-infection or unexplained hepatic dysfunction and has implications for patient management and public health surveillance. Nationally, accurate coding for serologic testing influences claims adjudication, lab reporting, and epidemiologic tracking.

Key payers included in the coverage discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code represents, typical clinical contexts for use, and what to expect in terms of service setting. The publication summarizes common billing considerations and provides benchmarking context where available. It also outlines clinical relevance, including when hepatitis D antibody testing is likely to be ordered and how it integrates with broader viral hepatitis workups.

This summary is intended for a national audience of coding professionals, laboratory managers, and policy analysts seeking a concise reference to the purpose and application of CPT code 86692 and the types of payer coverage and clinical scenarios in which the test is used. Data not available in the input is noted where applicable.